ZTS — Zoetis Inc.
$83.82
+$0.86 (+1.04%)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
Market Cap
$34.06B
Forward P/E
13.1x
52-Week Range
N/A
ZTS Price History
Revenue vs. Net Income
$9.5B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$2.3B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
27.1%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.3x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
6.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-2.4%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
